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ABSTRACT 
 
 
 Type II diabetes is a disorder that affects the ability of the body to produce or 
utilize insulin, and is characterized by hyperglycemia. The p53 tumor suppressor 
signaling pathway has been shown to play a role in maintaining glucose homeostasis in a 
process mediated by Ser18.  To better understand insulin resistance, we utilized a loss of 
p53 function model (phosphorylation mutant p53Ser23Ala) and a model where p53 is 
hyperactivated (model p44) to further define the role of p53 in insulin sensitivity in vivo.  
Insulin-mediated Akt activation was analyzed in various tissues as a marker for insulin 
sensitivity. Glucose homeostasis was measured through glucose and insulin tolerance 
tests.  It was found through these mouse models that p53 plays a vital role in regulating 
glucose homeostasis and insulin sensitivity. 
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BACKGROUND 
 
 
Diabetes and Glucose Dysregulation 
 Diabetes is a glucose dysregulation disease in which glucose is not taken up into 
cells of the body, resulting in serum hyperglycemia.  In Type 1 diabetes, the lack of 
glucose uptake results from the diminished production of insulin by pancreatic beta cells.  
Insulin normally facilitates glucose uptake by binding insulin receptors to initiate signal 
transduction pathways to upregulate glucose receptors, such as GLUT-1, on the cell 
surface.  Without insulin production, GLUT-1 is not upregulated, glucose is not taken 
inside the cells, and serum glucose becomes elevated.   
 Type 2 diabetes is the most common form of diabetes, and is one of the main 
causes of mortality worldwide (Kahn and Saltiel, 2001).  With this type of diabetes, the 
cells are considered insulin-resistant which is also coupled with glucose intolerance. 
Insulin-resistance occurs when the body does not respond to insulin. The problem is 
generally “post receptor”, meaning the pancreatic beta cells produce and secrete insulin, 
and the insulin binds insulin receptors, but the cells do not respond to the insulin binding. 
Glucose intolerance occurs when the produced insulin cannot initiate the metabolism of 
glucose into glycogen in the body’s liver and muscle cells, leading to the hyperglycemia. 
During glucose dysregulation, several areas of the body become detrimentally affected, 
especially the eyes, kidneys, nerves, and heart.  Type 2 diabetes is more prevalent in 
obese people, and is more common in African Americans, Latinos, Native Americans, 
and Asian Americans/Pacific Islanders, as well as the elderly population (American 
Diabetes Association, 2010). 
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 An important aspect of Type 2 diabetes is the inability of the body to maintain 
glucose homeostasis.  The normal body is able to maintain a constant plasma glucose 
level between 4 and 7 mM (72 to 126 mg/dL) either during or between periods of glucose 
ingestion. This tight homeostasis is maintained by absorption in the intestine and uptake 
of the glucose by the surrounding tissues.  Figure 1 summarizes how insulin regulates 
glucose uptake, production, and storage. Insulin increases glucose uptake into cells by 
binding the insulin receptor (blue in the diagram) to upregulate glucose transporters, such 
as GLUT-1 (red in the diagram).  Glucose transporters bind glucose transporting it across 
the cell membrane.  Insulin binding to its receptor also increases the uptake of amino 
acids using their amino acid transporters (green).  Glucose brought into the cell is 
converted to triglycerides, glycogen, or enters glycolysis (red arrows).  Prolonged binding 
of insulin to its receptor subsequently inhibits glucose production by those cells, and 
inhibits the conversion of triglycerides to fatty acids.  Thus, insulin serves as a powerful 
glucose homeostasis regulator (Kahn and Saltiel, 2001). 
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Figure 1.  Summary of Glucose Homeostasis by Insulin.  Insulin regulates glucose 
uptake and production, and promotes the synthesis and storage of carbohydrates, lipids 
and proteins (Kahn and Saltiel, 2001).  
 
 Many tissues in the body assist in glucose regulation (Figure-2). After glucose is 
absorbed through the intestine, the beta cells of the pancreas secrete insulin in response to 
the elevated plasma glucose levels. The principle role of the hormone insulin is to control 
the plasma glucose concentrations through stimulating glucose transport into muscle and 
fat cells, and reducing glucose output from the liver (Ogawa et al., 1998). As discussed 
above, insulin also causes a decrease in liver glucose production (from stored glycogen) 
and increases the level of glucose uptake in the liver, initiating its conversion into 
glycogen. It is essential to store glucose as glycogen because the glycogen molecule is 
small, less reactive than glucose, and is insoluble in water, meaning it will not affect the 
osmotic levels and pressure of the cells that store it.  When energy is needed, the 
glycogen store in liver cells can be converted back into glucose and distributed to the 
entire body.  This glycogen conversion also occurs when insulin levels are low or absent, 
triggering an unnecessarily high amount of glucose to convert from glycogen, leading to 
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a state of cellular hyperglycemia. Insulin also increases glucose storage, as glycogen, in 
fat and muscle cells. The glycogen produced in the muscle cells serves as an immediate 
energy source for these muscle cells only, and is not distributed throughout the body 
because these cells lack the necessary enzymes that allow the glucose to enter into the 
blood.  Fat cells release FFAs (free fatty acids) which cause a decrease in glucose uptake 
in muscle cells, a decrease in insulin secretion and increased glucose production from the 
liver.  FFAs derived from adipocytes are found to be elevated in the serum in insulin-
resistant organisms.  This suggests that this is a contributing factor to the insulin 
resistance of diabetes, causing obesity by inhibiting glucose uptake and glycogen 
synthesis.  This link may also suggest that the accumulation of triglycerides and fatty acid 
metabolites in muscle and liver are involved in insulin resistance (Ogawa et al., 1998; 
Kahn and Saltiel, 2001). 
 
Figure 2: Role of Different Organs in Glucose Homeostasis.  Diagram illustrates the 
interaction of various body systems and tissues in the regulation of glucose homeostasis 
through glucose uptake and insulin secretion (Kahn and Saltiel, 2001).   
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The Insulin Receptor 
 Insulin is the main hormone controlling essential energy functions, including 
glucose and lipid metabolism. Insulin elicits a variety of biological responses once bound 
to its receptor (SABiosciences, 2009).  Insulin receptors are part of the receptor tyrosine 
kinase subfamily that also includes insulin-like growth factor (IGF-I) receptor and the 
insulin receptor-related receptor (IRR).  These tetrameric proteins consist of two alpha 
subunits and two beta subunits.  The alpha subunit inhibits the tyrosine kinase activity of 
the beta subunit.  The insulin receptor, along with the IGF-I and IRR receptors, are also 
able to form functional hybrids.  If an inhibitory mutation arises in one of the receptors, it 
may affect the activity of the other two due to the formed hybrids (Kahn and Saltiel, 
2001; SABiosciences, 2009).  When insulin binds the insulin receptor on the surface of 
the cell it initiates several signal transduction pathways involving a variety of protein 
kinase molecules, whose result was shown as blue arrows in Figure 1: upregulation of 
the GLUT1 transporter, increased conversion of glucose to glycogen, and increased usage 
of glucose in glycolysis. Insulin mediates these effects via activation of signaling 
pathways (Figure 3) which utilize: adaptor molecules such the IRS (Insulin Receptor 
Substrates), the SHC (Src and Collagen Homologues) and the GRB2 (Growth Factor 
Receptor Binding protein-2); lipid kinases such as PI3K (Phosphatidylinositol 3-Kinase); 
small G-proteins like Rac; and serine, threonine and tyrosine kinases (Ogawa et al., 
1998). 
  
 10 
 
 
 
Figure 3. Summary of Kinase Activation in the Presence of Insulin.  Activation of the insulin 
receptor via insulin causes a cascade of biological effects on cells including stimulation of glucose 
transport, gene expression and alterations of cell morphology (SABiosciences, 2009).  
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One key pathway in insulin signal transduction is the Akt kinase pathway. The 
serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in 
cell signaling downstream of growth factors, cytokines, and other cellular stimuli. 
Abnormal loss or gain of Akt activation is an underlying cause of the physiological 
properties of a variety of complex diseases, including type-2 diabetes and cancer 
(Manning and Cantley, 2007).  
 
Akt Pathway 
  The Ser/Thr kinase Akt/Protein Kinase B pathway is highly conserved across a 
wide range of species, and is involved in many cellular processes.  Though it is has many 
roles, an important aspect of the Akt pathway is its role in regulating the metabolic 
effects of insulin in several target tissues.  Figure 4 summarizes the effect of the Akt 
pathway (up-regulation or down-regulation) in four insulin-responsive metabolic tissues. 
The role of Akt is not completely understood in the coordination of insulin action 
throughout the body, but Akt is known to be a key regulator of the insulin-signaling 
pathway that plays a role in glucose homeostasis (Whiteman et al., 2002).  Any 
disruption in the Akt pathway would lead to insulin resistance and glucose dysregulation, 
so understanding this pathway is important when studying of Type 2 diabetes.  
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Figure 4:  Summary of the Effects of the Insulin-Induced Akt Kinase 
Pathway.  Shown are the events up-regulated and down-regulated in insulin 
responsive metabolic tissues following activation of the Akt kinase pathway 
by insulin binding its receptor (Whiteman et al., 2002). 
 
 
p53 Functions 
 The p53 tumor suppressor has an important role in gene expression and genetic 
stability.  In almost fifty percent of all human cancers, p53 is mutated, causing an 
accumulation of DNA mutations, and the expression of dysfunctional cellular proteins 
(Steele et al., 1998). Many studies have shown that p53 is stressed-induced, and it 
functions by restricting the proliferation of abnormal cells (Kubbutat,1997; Olovnikov et 
al., 2008).  However, more recent studies have suggested that p53 also plays a role in 
cells under non-stress situations.  For example, p53 has been shown to contribute to the 
homeostatic regulation of different metabolic processes (Olovnikov et al., 2008). p53 acts 
as a transcription factor, and previous studies have shown that more than 500 genes are 
potentially regulated by p53 (Olovnikov et al., 2008).   
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 p53 is found to be expressed in multiple tissues in mice, including brain, pancreas, 
liver, muscle, and adipose tissue, many of which are involved in glucose homeostasis.  In 
addition to blocking cell division (for abnormal cells), the p53 pathway has also been 
noted to affect cellular metabolism.  Hyperglycemia has been shown to activate p53 and 
induce its phosphorylation (Schmitt et al., 1999) (Figure 5).  Shown in the diagram are 
two key phosphorylation sites (Ser18 and Ser23) located within the transactivation 
domain on the N terminal of the gene.  Other studies have correlated p53 with aging, age-
related insulin resistance, and diabetes (Rudolph et al., 1999). 
 
 
 
Figure 5:  Diagram of the Murine p53 Transcription Factor Protein.  Shown are the major 
domains of p53 protein, including its N-terminal transactivation domain on which the Ser18 and 
Ser 23 phosphorylation sites reside.  Also shown are its DNA-binding domain (diagram center), 
and its tetramerization domain which helps form complexes with other p53 molecules. 
 
 Research has linked p53 with the control of the Warburg effect in tumor cells 
(Luo et al., 2004).  The Warburg effect is described in cancer cells as increased glycolysis 
even when sufficient glucose is present.  Cells from p53-deficient mouse models show a 
decreased oxidative phosphorylation with an increased glycolysis (Macpherson et al., 
2004).  Thus, p53 plays a role in regulating glucose homeostasis. 
 
 
 
 
 
 14 
Ataxia Telangiectasia and the Sluss Lab Studies 
 The Sluss Laboratory at Umass Medical School has performed research on Ataxia 
telangiectasia (A-T).  In this disease, patients can develop multiple clinical pathologies, 
including neuronal degeneration, elevated risk of cancer, telangiectasias, and growth 
retardation (Spring et al., 2002; Lavin, 2008).  A-T patients may demonstrate an 
increased risk of insulin resistance and Type 2 diabetes (Bar et al., 1978).  ATM is a 
protein kinase mutated in some A-T patients, and has been implicated in metabolic 
diseases including insulin resistance (Shoelson, 2006).  ATM phosphorylates p53 on a 
site that regulates transcriptional activity (Sluss et al., 2004).   
 The Sluss Laboratory has studied the p53 Ser18 phosphorylation site for the 
regulation of glucose homeostasis using a p53Ser18A mouse model.  Mice are the most 
commonly used vertebrate species used for in vivo studies and are considered to be a 
prime model of inherited human disease because they share 99% of their genes with 
humans.  Because the ATM gene is mutated in some A-T patients, and this mutation 
correlates with insulin resistance, and ATM normally phosphorylates p53 at a site known 
to regulate transcriptional activity (Sluss et al., 2004), the next step for the Sluss 
laboratory was to test whether ATM regulates insulin-resistance through p53 
phosphorylation.  Figure 6 is a model of the p53 pathway in cell cycle checkpoint 
control.  Note that DNA damage leads to phosphorylation of p53 on Ser18 and Ser23 by 
the ATM/ATR signaling pathway.   A single phosphorylation of each site regulates 
different aspects of the p53 functions (shown as X, Y, and Z). 
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Figure 6:  Diagram of the p53 Pathway Cell Cycle Checkpoint Controls.  DNA 
damage is recognized by sensor proteins that relay the signal to transducers and lead to 
effectors that mediate a cellular response.  DNA activation leads to phosphorylation of 
p53 on Ser18 and Ser23 by the ATM/ATR signaling pathway.  A phosphorylation at 
either site regulates different aspects of p53 function (Sluss, personal communication). 
 
 
Sluss Laboratory p53Ser18Ala Mouse Model 
  The Sluss Laboratory studied insulin sensitivity in a mouse model in which the 
p53 phosphorylation site Ser18 was replaced with alanine (this site it highlighted with a 
red box in Figure 7).   The lack of phosphorylation at this p53 site was shown to increase 
metabolic stress and cause severe defects in glucose homeostasis compared to a wildtype 
mouse.  The p53Ser18Ala model also showed glucose intolerance and insulin resistance.  
Thus, the mouse model showed that p53 phosphorylation on a site known to be regulated 
by ATM is an important mechanism in the physiological regulation of glucose 
homeostasis (Sluss, personal communication). 
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Figure 7: Diagram of the Murine p53 Transcription Factor Showing the 
Phosphorylation Site Mutated in a Mouse Model.  The p53 N-terminal Ser18 
phosphorylation site (shown by a red box)  was replaced with alanine in the p53Ser18Ala 
mouse model.  
 
 
Mouse Models Used in This Project 
p53Ser23Ala 
 Two mouse models were utilized in this project, p53Ser23Ala and p44. 
p53Ser23Ala was the first model investigated in this project.  The p53 Ser23 
phosphorylation site has been proposed to work in conjunction with the previously 
studied Ser18 phosphorylation site, so a p53Ser23Ala mouse mutant was chosen for 
analysis. This model was originally created by Dr. Tyler Jacks, at MIT (Macpherson et 
al., 2004).  Figure 8 is a diagram of the p53Ser23A mutation, with the mutation site 
highlighted by the red box.  The murine p53Ser23 phosphorylation site is homologous to 
the p53Ser20 phosphorylation site in humans. The p53Ser23 site is also part of the 
ATM/ATR signaling pathway, and it is proposed that p53Ser23 may work in conjunction 
with p53Ser18 to regulate the function of p53.  Though these two sites could work in 
conjunction, they will be studied individually; the Sluss lab has already investigated the 
functions of p53Ser18A, so this project will focus on the p53Ser23A model to determine 
whether the mutation has an effect on the development of insulin resistance and glucose 
intolerance. 
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Figure 8: Diagram of Murine p53 Transcription Factor Mutated at the Ser23 
Phosphorylation Site.  The mutation site is shown by a red box.  Serine has been 
replaced with an alanine to produce the p53Ser23Ala mutant mouse model used in this 
project. 
 
 
p44 Mouse Model 
  The second model used in this project is p44.  This model was originally created 
by Dr. Heidi Scrable at the University of Virginia School of Medicine (Scrable et al., 
2005).  p44 is a truncated form of p53 that binds to p53 to make a dimer increasing its 
activity.  Figure 9 is a diagram of the p44 Transgene; the red box indicates the alternative 
translation start site at codon 41 located in the transactivation domain of the murine p53 
transcription factor.  p44 is a p53 homolog resembling a shorter p53 isoform.  Both 
human and murine p44 lack part of the N-terminal region present in full length p53 
(Scrable, 2004). p44 is naturally found at low levels in both mice and humans, and the 
genomic structure of the mouse p44 gene is identical to the structure of the human p44 
gene, indicating a this gene is highly conserved throughout evolution (Garcia et al., 
1998). It is thought that p44 interacts with p53 in mammals by enhancing its ability to 
suppress cell proliferation, however the functions of p44 are not yet fully understood.  
The overexpressed p44 transgenic mice created by Maier et al. (2004) shows signs of 
premature aging and are half the size of their non-transgenic littermates (Campisi, 2004). 
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The activity of p53 is thought to be elevated in p44 mice.  The transgenic mice have a 
very low occurrence of cancer development (an attribute of up-regulated p53).  These 
findings support the thought that hyperactive p53 can cause accelerated aging, and p44 
aids in this activity (Campisi, 2004).  We will be studying the effects of the 
overexpression of p53 caused by the p44 transgene model to understand whether this 
overexpression has an effect on the development of insulin resistance and glucose 
intolerance.
 
Figure 9:  Diagram of the p44 Transgene.  Figure shows a homolog of p53 used in the 
p44 transgenic mouse models.  The gene has a truncated transactivation domain, and is 
known to hyperactivate p53 transcription factor. 
 
 
 Both mouse models will be extensively studied to obtain data about potential 
alterations in glucose homeostasis.  The observations will be compared to a wildtype 
strain used as a control to verify all results.  The hope is that the two models will provide 
data showing whether the p53Ser23Ala phosphorylation site, and/or an increased p53 
activity for the p44 transgene, play a role in glucose homeostasis, and whether they affect 
the p53 transcription factor significantly in its role as a glucose regulator.  
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PROJECT PURPOSE 
 
 
Type 2 diabetes is a disorder characterized by glucose dysregulation contributed 
by insulin resistance.  Understanding the mechanism of pre-diabetic insulin resistance 
would provide a critical step towards identifying the early stages of the development of 
diabetes.  The potential role of p53 tumor suppressor in regulation of glucose homeostasis 
and insulin sensitivity is suspected but not proven. The proposed studies will examine the 
mechanisms underlying insulin resistance in two transgenic mouse strains, p53Ser23Ala 
(expressing a mutated p53 that can not be phosphorylated at the Ser23 site) and p44 
(expressing a truncated form of p53 that forms dimers with p53 increasing its activity).  
These studies are an extension of the Sluss Laboratory’s previous findings that 
p53Ser18Ala
 
mice (mutated at a different site) developed glucose intolerance and insulin 
resistance. The purpose of this research is to help define the contribution of the p53 
signaling pathway in glucose homeostasis, insulin signaling, and Type 2 diabetes. Insulin 
sensitivity and Akt pathway-insulin sensitivity in each mouse model will be monitored by 
Glucose and Insulin Tolerance Tests.  The mice will then be sacrificed, and protein and 
RNA will be purified from liver, muscle, and white fat tissues.  Protein expression of the 
Akt pathway will be monitored by immunoblots, and RT-PCR will show relative mRNA 
expression in these tissues. This project was completed as part of the Sluss Laboratory’s 
long term goal of defining the contribution of the p53 signaling pathway in glucose 
homeostasis, insulin signaling, and Type 2 diabetes. 
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METHODS 
 
Mouse Models 
Mouse Model Strains 
 The p53Ser23A mutant mouse strain was generously donated by Dr. Tyler Jacks, 
Center for Cancer Research, Massachusetts Institute of Technology. The p44 transgenic 
strain was generously donated by Dr. Heidi Scrable, Department of Neuroscience, 
University of Virginia School of Medicine. The mice were housed in specific pathogen-
free facilities accredited by the American Association for Laboratory Animal Care.  The 
Institutional Animal Care and Use Committee (IACUC) of the University of 
Massachusetts Medical School approved all studies using these animals.   
 
Animal Husbandry  
 Mice were handled in accordance with IACUC’s policy on the maintenance of 
mouse breeding colonies.  Gloves, hair net, face mask, shoe covers, and body suit were 
utilized when entering the mouse room area.  The specific animal husbandry methods 
followed include: specified weaning dates (21 days old), no more than 1 litter per cage, 
no more than 5 mice per cage, separate males and females, and appropriate breeding 
(same strains).  When sacrificed, mice were double killed in accordance with IACUC 
policy.   
 
Glucose Tolerance Tests 
  Mice were fasted overnight, then challenged by intraperitoneal administration of 
glucose (1g/kg body weight, IMS). Glucose levels were determined at 0, 15, 30, 45, 60 
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and 120 min after glucose stimulation. Blood glucose was measured with an Ascenzia 
Breeze 2 glucometer (Bayer).  
 
Insulin Tolerance Tests 
 Mice were fasted overnight, then challenged by intraperitoneal administration of 
insulin (0.75 units/kg body weight, Sigma, St. Louis, MO). Glucose levels were 
determined at 0, 15, 30, 60, 90 and 120 min after insulin stimulation. Blood glucose was 
measured with an Ascenzia Breeze 2 glucometer (Bayer).  
 
Tissue Harvesting and Storage 
 Mice were sacrificed in accordance with IACUC standards (double kill policy). 
Animals were immediately dissected, and target tissues and organs (liver, muscle, 
pancreas, spleen, white fat) were harvested, placed on 6 well plates, and frozen on dry 
ice.  Tissues were stored at -80°C. 
 
Mouse Genotyping 
 
Tail Section Digestion 
 A 1.0-1.5 cm section of mouse tail was cut and added to 700 µL of Lysis Buffer 
(50 mM Tris pH 7.5, 50 mM EDTA pH 8.0, 100 mM NaCl, 5 mM DTT, 0.5 mM 
Spermidine, and 1% SDS). 20 µL of freshly prepared 20 mg/ml Proteinase K (in sterile 
water) was added to each tube, then the tubes were shaken gently overnight, at 55°C.  
 
DNA Isolation  
 The eppendorf tubes were then spun at max speed for 5 minutes to pellet any 
tissue debris. The supernatant (containing DNA) was collected, and an equal volume of 
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phenol/chloroform/iso-amyl alcohol mix (25:24:1) was added.  Tubes were mixed by 
hand and then spun at max speed for 5 minutes. The aqueous (top) phase of each tube 
was collected, and an equal volume of absolute ethanol was added to tube, DNA was 
precipated by gentle inversion of the tubes. The DNA samples were rinsed once with 
80% EtOH, and let air dry.  An aliquot of 50-100 µL of TE was added to the DNA pellet, 
and dissolved overnight at room temperature. The DNA was stored at 4°C. 
 
PCR   
 The PCR consisted of making up a master mix solution that included Nuclease-
Free water (to final volume of 50 µl), 5x Green GoTaq® buffer, dNTP mix, GoTaq® 
DNA Polymerase (5U/µl), 25 mM MgCl2, and gene specific downstream and upstream 
primers.  The primers used for the p53Ser23A mice (MacPherson, 2004) were:  
5’-AGCCTGCCTAGCTTCCTCAGG-3’ and 5’-CTTGGAGACATAGCCACACTG-3’. 
The primers used for the p44-Tg mice (Scrable, 2004) were:  
5’-AAGCCTCGAAGTAAGTTGGATGCCTAG-3’ and 
5’-TGGCGGGATGTATCTTAAACCTTCC-3’. This master mix was added to 2 µl of 
template DNA, then placed into the thermocycler to undergo an appropriate PCR cycle.  
All PCRs were performed in a DNA Engine PTC 200.  All PCR reactions were then run 
on a 1% agarose gel to determine the genotype of each mouse.  
 
RT-qPCR 
RNA Isolation from Liver, Muscle, and Fat Tissues 
  Total RNA from liver, muscle, and fat tissues were prepared using RNeasy kits 
(Qiagen) following the manufacturer’s instructions. The purified RNA was subjected to 
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an additional DNase treatment (10 µl DNase and 70 µl DNase buffer, Ambion) to ensure 
removal of contaminating genomic DNA prior to final column purification. First and 
second elution RNA concentrations were read on a Thermo Nanodrop 2000 
Spectrophotmeter.  Purified RNA samples were frozen on dry ice and stored at -80°C. 
 
RNA Clean-up 
 The RNA clean-up consisted of a DNase treatment (Ambion) followed by 
RNeasy kits (Qiagen), according to both manufacturer’s instructions. 10 µg of the 
isolated RNA sample, in a total volume of 80 µl nuclease-free water, was added to a mix 
containing 2 µl DNase (Ambion), 10 µl 10X Buffer (Ambion), and 8 µl nuclease-free 
water. The samples were incubated for 20 minutes at 37°C, and then 1 µl DNase 
(Ambion) was added to each sample. The samples were incubated again for 20 minutes at 
37°C, and then 10 µl inactivation buffer (Ambion) was added to each sample and mixed 
for 2 minutes at room temperature. The samples were spun at max speed for 2 minutes, 
and supernatants were transferred to a new tube; the RNeasy clean-up kit (Qiagen) 
instructions were then followed. Cleaned RNA samples were frozen on dry ice and stored 
at -80°C. 
 
cDNA Synthesis 
 cDNA was prepared using Superscript III (Invitrogen) with random hexamers and 
0.5 µg -1.0 µg of RNA per tissue, following the manufacturer’s instructions for First-
Strand cDNA Synthesis.  cDNA samples were collected by brief centrifugation and 
stored at -20°C. 
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RT-qPCR 
 The relative expression of mRNA was examined by quantitative PCR analysis. 
Quantitative real-time PCR was performed on a Biorad Cycler using SyBr Green master 
mix (Biorad).  The primer sequences for the murine genes are listed in below in Table 1. 
All samples were examined in triplicate, and values were normalized for baseline 
expression and for expression of GAPDH.  Calculations of fold change were made using 
the ∆∆Ct method.  Statistical significance was calculated using CT values. 
 
 
Table 1:  Primers Used for Real Time RT-qPCR Analysis 
 
Primers Strand  Code 
Gapdh Sense (5’-CTTCACCACCATGGAGAAGGC-3’; 
 Antisense 5’-GGCATGGACTGTGGTCAT-3’) 
Trp53 Sense (5’-TGAAACGCCGACCTATCCTTA-3’; 
 Antisense 5’-GGCACAAACACGAACCTCAAA-3’) 
Mdm2 Sense (5’-TGACACCAGAGCTTAGTCCTG-3’; 
 Antisense 5’-GCGTCTCGTAACGAATAAGGC-3’) 
Zfp385a Sense (5’-ACATTGAGCACCGCTATGTCT-3’; 
 Antisense 5’-CTCTCTTGGATGAGGGTCTGATA-3’) 
Sesn1 Sense (5’- GTGGACCCAGAACGAGATGACGTGGC -3’; 
 Antisense 5’- GACACTGTGGAAGGCAGCTATGTGC -3’) 
Sesn2 Sense (5’-TCCGAGTGCCATTCCGAGAT-3’; 
 Antisense 5’- TCCGGGTGTAGACCCATCAC-3’) 
Sesn3 Sense (5’-  GCGAGGAGAAGAACATTTGCC-3’; 
 Antisense 5’- CCAAACATACAGTGAACATAGT-3’); 
Sco2 Sense (5’- GTGGACCCAGAACGAGATGACGTGGC-3’; 
 Antisense 5’-GACACTGTGGAAGGCAGCTATGTGC -3’) 
 
Immunoblots 
Preparation of Tissue Protein Lysates 
 Animal tissues were homogenized in triton lysis buffer (1X triton lysis buffer 
(TLB, 20 mM Tris pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% Triton lysis, 10% glycerol) 
containing protease and phosphatase inhibitors (5 µg/ml aprotinin, 5 mg/ml leupeptin, 5 
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mg/ml PMSF, 1 mM sodium orthovanadate, 25 mM beta-glycerophosphate). Protein 
samples were flash frozen in liquid nitrogen and stored at -80°C. 
 
BCA Protein Assay   
 Protein samples and standards were prepared using the BCA Protein Assay Kit 
(Pierce) according to manufacturer’s instructions. In each well, 2 µl of tissue lysate 
sample was added to 23 µl of sterile water, then 200 µl of working reagent was added to 
each sample well and mixed. The plate was incubated at 37C for 30 minutes, and then 
the absorbance was read at 550 nm on a Thermo Multitask Ascent plate reader. The 
resulting concentrations were used to create the loading samples for the Western Blots. 
Each sample had 50 µg of protein in a total volume of 50 µl; 10 µl of Laemmli’s SDS-
sample buffer (6X, reducing) was added to the appropriate amount of protein sample and 
mixed well. 1X triton lysis buffer (TLB, 20 mM Tris pH 7.4, 137 mM NaCl, 2 mM 
EDTA, 1% Triton lysis, 10% glycerol, 5 mg/ml PMSF, 1 mM sodium orthovanadate, 25 
mM beta-glycerophosphate) was added to each protein sample to bring the final total 
volume to 50 µl. 
 
Immunoblot Analysis 
 Tissues extracts were examined by immunoblot analysis using primary antibodies 
to Akt and phospho-Ser473 Akt (Cell Signaling). 50-100 µg of cell extract were run on a 
10% acrylamide gel with a 20% SDS buffer to separate proteins.  Proteins were then 
blotted onto Immobolin-P (Biorad), using transfer buffer, following standard techniques.  
The membrane was blocked in a solution of TBS-T [TBS-T, 10 mM Tris pH 8.0, 150 
mM NaCl, 0.05% Tween] with 10% skim milk for 1 hour.  Primary antibodies (6 ml 
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TBS-T 10% milk with 6 µl of anti-phospho-AktSer472, Cell Signaling) were added to the 
membrane and incubated overnight at 4C.   The membrane was washed three times in 
TBS-T, for 5 minutes each time, and incubated with secondary antibodies (1:10,000 anti-
mouse:block) for one hour.  The membrane was washed again in TBS-T.  Membranes 
were developed with chemilumenescence technique (GE Healthcare).  
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RESULTS 
 
The purpose of this project was to assess the role of the p53 tumor suppressor 
pathway in maintaining glucose homeostasis. The ability to metabolize glucose and 
utilize insulin was monitored in two transgenic mouse models, a p53Ser23A mutant in 
which p53 cannot be phorphorylated at site 23, and an overexpression p44 model in 
which the activity of p53 is increased. 
 
Mice Genotype and Phenotype 
 It was imperative to genotype all mouse strains, as this ensures correct breeding 
and strain conformation. The genotyping process started by sterilely cutting 
approximately 1 cm of each mouse tail, usually as they mice were weaned, and digesting 
the tail tissue to produce an aqueous solution from which DNA was isolated. The tail 
DNA was then isolated, and each mouse sample was analyzed by PCR. The PCR 
products were run on a 1% agarose gel and then analyzed to determine the genotype of 
each mouse. Figure 10 is a photograph of mutant mice strains compared to WT mice 
DNA samples run on the gel to determine genotype. When looking at the p53Ser23A 
mutant mice gel (Figure 10A), a band at 280 bp indicates WT allele, and a band at 320 
bp indicates a mutant allele; if these mice have both bands they are heterozygous 
p53Ser23A mutants, and if they have only one band, they are either homozygous WT or 
p53SerA depending on band location.  In Figure 10A, Lane 4 is an example of WT (+/+), 
Lane 5 is an example of a heterozygous mutant (+/-), and Lane 6 is an example of a 
homozygous mutant (-/-). When looking at the p44 transgenic mice gel (Figure 10B), a 
band at 289 bp indicates that the p44 transgene is present; however this gel does not 
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allow for the distinction between hemizygous and homozygous mice. In Figure 10B, 
Lane 5 is an example of a transgenic mouse (either +/- or -/-), and Lane 6 is an example 
of a WT mouse (+/+). 
 
                A: p53Ser23A            B: p44-Tg 
  
 
Figure 10. Gel of PCR Amplicons from Tail Digests for Genotyping Mutant and Wildtype Mice. (A) 
p53Ser23A mutant mice tail digest compared to wildtype mice. In 10A, the mutant mice are categorized as 
heterozygous (2 bands) or homozygous (1 band at 320 bp). In 10B, the transgenic mice are categorized as 
possessing the transgene if there is a band present.   
 
 
 The phenotype of each mouse strain can also be used to aid in the verification of 
the strain, especially in the p44-Tg mice. It is thought that p44 interacts with p53, 
affecting its ability to modulate gene expression and increasing its ability to suppress cell 
proliferation.  Transgenic mice that overexpress p44 show signs of premature aging and 
are very small (Campisi, 2004). This is especially true in the homozygous p44-Tg mice, 
and these mice can almost always be accurately assessed based on size alone as they can 
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be half the size and weight of the WT mice. All of the mice used in the Glucose 
Tolerance Test (GTT) (and Insulin Tolerance Test ITT since the same mice were used) 
were weighed prior to experiments. The average weight of the eight p44-Tg mice used in 
the GTT and ITT experiments was 20% less than the average weight of the 17 WT mice 
used in the same GTT and ITT experiments, seen in Table 2.  The p44-Tg were weighed 
(and tested) at an earlier age than the p53Ser23A mice as they had a lower life 
expectancy due to the hyperactivation of p53, which increased the rate of aging. Table 2 
also shows that the p53Ser23A mice were an average of 10% heavier than the WT strain; 
this is consistent with a high-fat body accumulation (Ikemoto et al., 1994). 
 
Genotype  
 
# Mice  
 
     Age  
 
Weight (g)  
 
Wildtype  
 
   10  
 
5 months  
 
     30  
 
p53Ser23A  
 
   12  
 
5 months  
 
     33  
 
Wildtype  
 
   17  
 
3 months  
 
     30  
 
p44-Tg  
 
 
    8  
 
3 months  
 
     24  
 
 
Table 2. Average Weights of the p53Ser23A and p44-Tg Mice Compared to WT 
Mice. Wildtype and p53Ser23A mice were weighed at 5 months, while p44-Tg mice 
were weighed at 3 months due to their early death rates.  p53Ser23A mice weighed 10% 
more than the WT, which is consist with a high-fat body weight leading to a pre-diabetic 
state. The p44-Tg weighed 20% less than the WT because the homozygous phenotype of 
this model is characterized by a smaller body size.  
 
 
Analysis of p44 Transgenic Mice 
 
 The p44 transgenic mice and WT mice were subjected to a Glucose Tolerance 
Test (GTT) and an Insulin Tolerance Test (ITT) at 3 months of age. The GTT (Figure 
11) was performed 1 week before the ITT (Figure 12).  Prior to the GTT, the mice were 
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fasted overnight.  Glucose (1g/kg body weight, IMS) was administered via an 
intraperitoneal injection, and blood glucose levels were measured with a an Ascenzia 
Breeze 2 glucometer (Bayer) at 0, 15, 30, 45, 60 and 120 min after glucose stimulation. 
The blood was drawn from a tail cut made at the start of the GTT. The determined 
glucose levels were graphed and analyzed to assess whether glucose intolerance occurs in 
the p44-Tg mice. The GTT is an essential test for diabetes research involving mouse 
models as it is the only means of identifying impaired glucose tolerance (Andrikopoulous 
et al., 2008). The GTT measures the animal’s ability to metabolize glucose. The GTT 
starts with an i.p. injection of glucose, causing glucose levels in the body to dramatically 
increase. The body should release insulin in response to this increased glucose level. The 
amount of blood glucose should increase immediately, as glucose is absorbed into the 
body and then decrease as the secreted insulin helps converts glucose to glycogen. At 120 
minutes post administration of glucose, the blood glucose levels should return to basal 
levels (assumed by the WT blood glucose level at t= 120 minutes).  
  
 The p44 transgenic mice were found to exhibit glucose intolerance compared to 
the wildtype mice (Figure 11). This is seen in the elevated basal glucose levels, as WT 
mice had approximately 90 mg/dL basal glucose, while p44-Tg mice showed 
approximately 125 mg/dL glucose.  As expected, the blood glucose levels increased 
significantly at t= 15 minutes post-injection. Post administration of glucose, the p44-Tg 
mice blood glucose levels increased to a greater level than the WT mice.  Although the 
p44-Tg mice blood glucose levels decreased over time, they consistently remained above 
the WT levels.  Statistically significant differences (P<0.05) between the glucose levels in 
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the WT mice and transgenic mice occurred at t= 0 and t=15 minutes after glucose 
stimulation (denoted by asterisks in the figure). 
 
 
 
Figure 11. In Vivo Glucose Tolerance Test for p44-Tg Mice Compared to WT Mice. 
The GTT showed that the p44 transgenic mouse showed glucose intolerance compared to 
the wildtype mice, illustrated by the slightly elevated basal glucose levels, and a 
significant increase in glucose levels at t= 15 minutes. Statistically significant differences 
between glucose levels of the WT and transgenic mice strains are indicated  (*, P < 0.05).  
 
 
 The insulin tolerance test (ITT) was performed one week after the glucose 
tolerance test on the same p44-Tg and WT mice. Prior to the start of the ITT, the mice 
were not fasted overnight; The time = 0 minutes glucose reading was taken before the 
stimulation with insulin from a tail cut, making this time point an indication of basal level 
glucose. The insulin (0.75 units/kg body weight, Sigma, St. Louis, MO) was administered 
via an intraperitoneal injection, and blood glucose levels were measured from the tail cut 
with a an Ascenzia Breeze 2 glucometer (Bayer) at 15, 30, 60, 90 and 120 min after 
insulin stimulation. The determined blood glucose levels were graphed and analyzed to 
assess whether insulin resistance occurs in the p44-Tg mice. The administration of insulin 
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decreases serum glucose; the ITT measures the body’s ability to utilize insulin. In the 
presence of insulin, the body should stop the breakdown of glycogen into glucose in the 
liver, and initiate the transformation of glucose into glycogen, thus the blood glucose 
levels should decrease in the presence of insulin. The large amount of injected insulin 
should induce hypoglycemia.  As homeostasis is achieved in the body, the blood glucose 
measurements should level off in a straight line. Since the t=0 glucose reading was taken 
prior to insulin stimulation, this reading can be used as a basal level.  
 
 The p44 transgenic mice showed insulin sensitivity compared to the wildtype 
mice (Figure 12), despite their elevated basal glucose levels. Both the wildtype and 
transgenic mice exhibited elevated basal glucose readings (above 126 mg/dL), though 
this could be because the mice had eaten right before the start of the ITT as they were not 
starved overnight. Glucose levels decreased by almost twice the amount in p44-Tg mice 
compared to wildtype mice (WT mice dropped 71.65 mg/dL, while p44-Tg mice dropped 
134.0 mg/dL). After the steep decrease in glucose levels, the p44-Tg glucose levels began 
to increase. Unlike the WT mice, who’s glucose measurements leveled off (creating a 
linear line), the p44-Tg mice glucose measurements kept increasing. Though the WT and 
p44-Tg mice ended with similar glucose levels, the p4-Tg mice had an increasing slope, 
meaning the insulin and glucose levels were not reaching a homeostasis; instead the 
glucose levels were increasing. The t= 120 minutes post insulin stimulation had the 
second highest glucose level. Based on this quick, large drop in glucose levels, coupled 
with increasing (not steady) glucose levels, the p44-Tg animals appear to be more insulin 
sensitive than the WT mice, and suggests that the p44-Tg mice have an insulin/Akt 
pathway in which the pathway stimulation is impaired. The statistically significant 
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differences (P < 0.05) between glucose levels of the WT and transgenic mice strains 
occurred at t=0 minutes (shown as an asterisk). 
 
 
 
Figure 12.  In Vivo Insulin Tolerance Test for p44-Tg Mice Compared to WT Mice. Although basal 
glucose levels are elevated in the p44-Tg model, these mice are still sensitive to insulin. Glucose levels 
decreased by almost twice the amount in p44-Tg mice compared to wildtype mice (WT mice dropped 71.65 
mg/dL, while p44-Tg mice dropped 134.0 mg/dL). Therefore, the p44-Tg animals are more insulin 
sensitive. Statistically significant differences between glucose levels of the WT and transgenic mice strains 
are indicated (*, P < 0.05).  
 
 
Analysis of p53Ser23A Mutant Mice 
 
 The p53Ser23A mutant mice and WT mice were subjected to a Glucose Tolerance 
Test and an Insulin Tolerance Test at 5 months of age. The GTT (Figure 13) was 
performed 1 week before the ITT (Figure 14).  Prior to the GTT, the mice were fasted 
overnight. The glucose (1g/kg body weight, IMS) was administered via an intraperitoneal 
injection, and blood glucose levels were measured with a an Ascenzia Breeze 2 
glucometer (Bayer) at 0, 15, 30, 45, 60 and 120 min after glucose stimulation. The blood 
was drawn from a tail cut made at the start of the GTT. The determined blood glucose 
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levels were graphed and analyzed to assess if glucose intolerance occurs in the 
p53Ser23A mutant mice.  
  
 The p53Ser23A mutant mice exhibited glucose intolerance compared to the 
wildtype mice (Figure 13).  The p53Ser23A mutant mice glucose levels increased to a 
much higher point than the WT mice, but the glucose was converted into glycogen as 
seen in the final glucose measurement, as the WT and p53Ser23A levels were almost 
equal. The glucose intolerance exhibited by the p53Ser23A mutant mice is clearly 
exhibited by the significantly increased glucose levels at t=15 and t= 30 minutes post 
glucose stimulation. These time points are the statistically significant differences 
(P<0.05) between the glucose levels in the WT mice and mutant mice.  
 
 
 
Figure 13.  In Vivo Glucose Tolerance Test for p53Ser23A Mice Compared to WT 
Mice. The p53Ser23A GTT showed that p53Ser23A mouse mutant exhibited elevated 
glucose intolerance compared to the wildtype mice shown by the significantly increased 
glucose levels. Statistically significant differences between glucose levels of the WT and 
the p53Ser23A mutant mice strains are indicated (*, P < 0.05).  
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 The insulin tolerance test was performed one week after the glucose tolerance test 
on the same p53Ser23A mutant and WT mice. Prior to the start of the ITT, the mice were 
fasted overnight. A time = 0 minutes basal glucose level was taken before the stimulation 
with insulin from a tail cut. The insulin (0.75 units/kg body weight, Sigma, St. Louis, 
MO) was administered via an intraperitoneal inject, and blood glucose levels were 
measured from the tail cut with a an Ascenzia Breeze 2 glucometer (Bayer) at 15, 30, 60, 
90 and 120 min after insulin stimulation. The determined glucose levels were graphed 
and analyzed to assess whether insulin resistance occurs in the p53Ser23A mutant mice. 
 
 As was observed with the p44 mice, the p53Ser23A mutant mice exhibited insulin 
sensitivity when compared to the wildtype mice (Figure 14).  In this case the initial drop 
in glucose levels was identical between WT and p53Ser23A mice. Unlike the p44 mice, 
where the difference in glucose drop was used to declare insulin sensitivity, the insulin 
sensitivity in the p53Ser23A mice rests in the rapid return to glucose levels equal to the 
glucose levels before the insulin injection. The glucose levels in the p53Ser23Ala mutant 
mice initially decreased, but then steadily increased, and at t=120 minutes post insulin 
stimulation, the glucose levels were equal to basal level glucose readings, showing the 
mutant mice to be in a state of hyperglycemia relative to WT mice (although the actual 
final serum glucose level of approximately 90 mg/dL falls within the norm for mice of 72 
to 126 mg/dL).  The insulin sensitivity in the p53Ser23A mutant mice is characterized by 
rapidly elevated glucose levels, compared to the wildtype mice, that were unable to return 
to basal glucose levels (remaining at 97 mg/dL); thus, the p53Ser23A mutant animals are 
more insulin sensitive than the WT strain.  The statistically significant differences (P < 
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0.05) between glucose levels of the WT and mutant mice strains occurred at t= 60 , t=90, 
and t= 120 minutes post insulin stimulation. 
 
 
 
Figure 14.  In Vivo Insulin Tolerance Test for p53Ser23A Mice Compared to WT 
Mice. The p53Ser23A ITT showed that the mutant animals exhibited glucose levels that 
became rapidly elevated, compared to the wildtype mice, and were unable to return to 
basal glucose levels (remaining at 97 mg/dL); thus, the p53Ser23A mutant animals are 
more insulin sensitive than the WT strain. Statistically significant differences between 
glucose levels of the WT and the p53Ser23A mutant mice strains are indicated (*, P < 
0.05).  
 
 
 The relative expression of the p53-inducible sestrin gene in WT mouse and 
p53Ser23a mouse liver was determined through an Real-Time Polymerase Chain 
Reaction (RT-qPCR). Highly conserved and p53-inducible, the sestrin gene occurs in 
three forms: sestrin 1, sestrin 2, and sestrin 3. The relative expression of sestrin (sesn) in 
the liver serves as a control to the functionality of p53.  Wildtype p53 is functional, and 
thus it should induce high levels of all three sesn proteins, as it does in Figure 15 (WT 
represented by the blue bar). This shows that the WT has a functional p53 domain. The 
p53Ser23A mutant should show decreased levels of sesn activity since the serine23 
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phosphorylation site has been mutated into an alanine. This seems to be true in the in 
Figure 15, though none of the difference in relative expression of sesn 1, sesn 2, or sesn 
3 are statistically important (P < 0.05). It was discovered that the sesn standards used in 
this RT-qPCR were old and therefore not expressing true levels of protein.  
 
 
Figure 15.  RT-PCR Analysis of the Relative Sestrin Gene Expression in the Liver of 
WT and p53Ser23A Mice.   Expression was measured by quantitative RT-PCR (mean ± 
S.E.M.; n = 3). Sestrins are highly conserved p53-inducible proteins and may play a role 
in regulating ROS levels. The relative expression was corrected for the amount of Gapdh 
mRNA in each sample and was normalized to a value of 1 for wild-type mice. There are 
no statistically significant differences between WT and p53Ser23A mice (P < 0.05).   
 
 
Insulin Signaling Pathway 
 
 Since insulin functions are the principal facet of glucose metabolism and the 
development of Type 2 diabetes, the efficacy of the insulin signaling pathway was 
studied.  Studying the wildtype mice strain for an understanding of how the Akt pathway 
functions in response to insulin is necessary for a control (see Figure 16). This was 
achieved by treating WT liver and muscle with insulin to phosphorylate the Akt Ser473 
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site, which activates the Akt pathway.  These samples were then examined via 
immunoblot analysis.  
 In liver and muscle in the presence of insulin, Akt was found to be active, 
showing an increase in the band intensity for Ser473 phosphorylation, while the 
intensities of total Akt (lower panel) were approximately equal. In the absence of insulin, 
less phosphorylated Akt was observed, as this shows the Akt proteins are present but not 
phosphorylated. Not analyzed was Akt activation in tissues of p53Ser23A and p44-Tg 
mice as a method for investigating the insulin signaling pathway.  
 
 
 
 
Figure 16. Insulin Signaling in p53 Wildtype Liver and Muscle Tissues. Activation of 
Akt in wildtype liver and muscle in response to insulin was analyzed by immunoblot 
analysis.  Ser
473
 phosphorylation was used as a measaure of Akt activation , and  was 
induced in the liver and muscle in response to insulin treatment.  
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DISCUSSION 
 
 The purpose of this project was to assess the role of the p53 tumor suppressor 
pathway in maintaining glucose homeostasis. Two mouse models, a “knock down” 
p53Ser23A mutant strain in which the p53 Ser23 site can not be phosphoryated, and an 
overexpression p44 transgenic strain showing increased p53 activity, were studied to 
analyze the role of p53 in glucose homeostasis. Both strains exhibited signs of glucose 
intolerance and insulin sensitivity, though in the p44-Tg strain the glucose intolerance 
was more pronounced than the insulin sensitivity, and in the p53Ser23A strain the insulin 
sensitivity was more pronounced than the glucose intolerance.  
 
 The p44 transgenic strain’s GTT exhibited glucose levels that increased to a much 
higher point than the WT strain did. The glucose levels decreased over time, but they 
remained elevated compared to the WT glucose levels. This elevation of glucose is what 
characterizes the p44-Tg mice glucose intolerance. The ITT showed that the p44-Tg mice 
were insulin sensitive. The elevated basal glucose levels in the mice indicate that there 
could be a problem with the insulin/Akt pathway because there is an abnormally high 
blood glucose level (leading to a state of hyperglycemia) indicating that insulin is not 
initiating the conversion of glucose to glycogen. Once these mice were challenged with 
insulin, the glucose levels dropped, showing that the insulin receptors are still 
functioning, though not as they should be. It could also mean that the p44-Tg mice are 
not producing enough insulin. This could explain the unusually high basal glucose levels 
and why the glucose levels decreased when challenged by insulin. Once the glucose was 
being converted into glycogen, the blood glucose levels dropped, but they dropped too 
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low, indicating the body is unable to regulate insulin production and glucose metabolism 
because it is unable to reach homeostasis. The decrease in glucose levels in the p44-Tg 
mice was almost double the drop seen in the WT mice. After the glucose levels dipped 
they started increasing, not leveling off as would be expected if homeostasis was 
achieved (this linear leveling off can be seen in the WT mice). It seemed that the glucose 
levels were increasing continually, and the final time point, t= 2 hours post insulin 
administration was the second highest time point. This suggests that the p44 transgenic 
mice have an impaired insulin/Akt pathway. 
 
 The p53Ser23A mutant mice glucose tolerance test showed that these mice 
exhibited glucose intolerance. The glucose levels raised to a higher point than in the WT 
mice, but were able to stabilize at a glucose measurement comparable to the WT’s final 
glucose reading, indicating glucose homeostasis was achieved. The increased glucose 
readings imply that these mice were unable to convert glucose to glycogen as efficiently 
as the WT mice could.  The p53Ser23A mutant mice ITT showed that these mice exhibit 
insulin sensitivity. The ITT showed that the glucose levels decreased in response to the 
administration of insulin, but then steadily increased, indicating that the insulin was able 
to initiate the conversion of glucose to glycogen, but the effect was short-lasted. The 
glucose levels increased after t= 30 minutes post insulin stimulation, and continued to 
increase; at t= 120 minutes post insulin stimulation, glucose levels were equal to basal 
glucose levels, and the p53Ser23A mice were in a state of hyperglycemia.  
 
 Both the p53Ser23A mutation, a “knockdown” of p53 and the p44 transgene that 
overexpresses p53, showed glucose intolerance and insulin sensitivity. The knockdown 
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mutation showed a greater insulin sensitivity than glucose intolerance, indicating that 
these mice could have an impaired insulin receptors because these mice do not seem able 
to utilize insulin to convert glucose to glycogen. The p53Ser23A mice did not exhibit an 
elevated basal glucose level, indicating the mice are able to maintain glucose 
homeostasis. The GTT showed the mutant mice were able to convert glucose to 
glycogen, but at a slower rate; thus the p53Ser23A mice are able to utilize insulin to 
convert glucose to glycogen, but at an impaired rate compared to the wildtype mice. The 
p44 transgenic mice cause an overexpression of p53 in these animals; when p53 is 
overexpressed, these mice were more glucose intolerant than insulin sensitive. When the 
p44-Tg mice were challenged with glucose, their blood glucose levels skyrocketed to 
over 400 mg/dL, while the wildtype mice remained around 250 mg/dL. This severe 
increase in glucose levels indicate the mice are unable to produce enough insulin to 
respond to the administered glucose, or, if the mice are producing insulin, their insulin 
receptors (or Akt pathway) or non-functional. The elevated basal glucose levels, 
illustrated on the ITT, correspond to this idea because this shows the mice are unable to 
regulate glucose levels.  
 
 The exact function of the p53 tumor suppressor pathway in maintaining glucose 
homeostasis remains unknown, but altering its functions in any manner has an effect on 
glucose homeostasis, indicating that p53 does play a role. The two mouse models utilized 
in this project, the “knockdown” model of the Ser23 phosphorylation site and the 
overexpression of p53 through p44 alter the functions of p53 in opposing ways, therefore 
it was expected that the results from these polar models would reflect this contrast. 
However, this was not the case as both mouse models resulted in glucose intolerance and 
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insulin sensitivity, though in differing degrees. This outcome illustrates the complexity of 
both the insulin signaling pathway and the functions of p53. Further tests studying the 
p53Ser23A mutation and the p44 transgenic strain need to be completed for a more 
complete understanding of the p53 tumor suppression pathway’s role in glucose 
homeostasis. Specifically, these tests should include a continuation of the RT-qPCRs (to 
show relative protein expression to test for the functionality of p53) and western blots (to 
test the functionality of the Akt pathway).  Also, other members of the insulin signaling 
pathway could be monitored for activity to determine whether the alteration in p53 
activity affects their activation. 
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